Ascendis Pharma Reports Third Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Nov 14, 2024
– YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3
– TransCon CNP NDA submission for achondroplasia planned for Q1 2025 followed by MAA submission planned for Q3 2025
Read more at globenewswire.com
